Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Arrowhead announced interim Phase 1/2a data for ARO-MAPT showing mean CSF total tau reduction of 73% at Day 105, with a maximum individual reduction of 85%, in healthy volunteers. The results are the first clinical validation of subcutaneous siRNA delivery across the blood-brain barrier, supporting potential quarterly or less-frequent dosing; safety was clean with no serious adverse events.
Key figures
- Drug Name
- ARO-MAPT
- Phase Of Trial
- Phase 1/2a
- Durability
- Day 105 is 90 days after final dose, supporting potential quarterly dosing
- Study size
- ~64 healthy volunteers and up to 48 early Alzheimer's patients
- Csf tau max reduction
- 85%
- Csf tau mean reduction
- 73% at Day 105 (12.8 mg/kg)
- Dose dependent reductions
- 40% (2.1 mg/kg) and 69% (6.4 mg/kg) at Day 105
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.